A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours. In the experimental lung metastasis xenograft models, treatment with bexarotene inhibited the development of the lung tumour nodule formation compared to control. In vivo angiogenesis assay utilising gelfoam sponges, bexarotene reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic fibroblast growth factor to various extent. To determine the basis of these observations, human breast and non-small-cell lung cancer cells were subjected to migration and invasion assays in the presence of bexarotene. Our data showed that bexarotene decrease migration and invasiveness of tumour cells in a dose-dependent manner. Furthermore, bexarotene inhibited angiogenesis by directly inhibiting human umbilical vein endothelial cell growth and indirectly inhibiting tumour cell-mediated migration of human umbilical vein endothelial cells through Matrigel matrix. Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases. The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma. Collectively, our results suggest a role of bexarotene in treatment of angiogenesis and metastasis in solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“Furthermore, antiangiogenesis approach may avoid the development of acquired drug resistance associated with conventional anticancer therapy since this approach targets genetically stable endothelial cells rather than genetically unstable tumour cells (Boehm et al, 1997).”
BackgroundPPARγ as a therapeutic target for tumor angiogenesis and metastasis
Panigraphy, D., Huang, S., Kieran, M. W., & Kaipainen, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.2014 · Cited by 137 · cited 1×
“In addition, several reports have indicated the involvement of PPARg agonists in expression of angiogenic and matrix metalloproteinase factors (Fauconnet et al, 2002; Worley et al, 2003; Panigrahy et al, 2005).”
Background
Cited by
The tumour microenvironment as a target for chemoprevention
Albini, A., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2067 · Cited by 823
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637
A gene expression signature identifies two prognostic subgroups of basal breast cancer
Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., Tallet, A., Chabannon, C., Extra, J.-M., Jacquemier, J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0897-9 · Cited by 290
Bexarotene: A promising anticancer agent
Qu, L., & Tang, X. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1140-4 · Cited by 78
The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma
Huen, A. O., & Kim, E. J. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2015.05.007 · Cited by 52
Metadata
- Authors
- Yen, W.-C., Prudente, R. Y., Corpuz, M. R., Negro-Vilar, A., & Lamph, W. W.
- Venue
- British Journal of Cancer
- Published
- 2006-02-21
- Volume
- 94
- Issue
- 5
- Pages
- 654-660
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2037912518
- Cited by
- 56
- References
- 2
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. https://app.cochat.ai/papers/10.1038/sj.bjc.6602995
- The paper
- Yen, W.-C., Prudente, R. Y., Corpuz, M. R., Negro-Vilar, A., & Lamph, W. W. (2006). A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.